Eyegate Pharmaceuticals, Inc.

Quick facts

Marketed products

• Dexamethasone Phosphate Ophthalmic Solution

Phase 2 pipeline

• EGP-437 with EyeGate® II System · Ophthalmology
  EGP-437 is a corticosteroid delivered directly to the eye via the EyeGate® II iontophoresis system to reduce ocular inflammation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Eyegate Pharmaceuticals, Inc. portfolio CI brief
• Eyegate Pharmaceuticals, Inc. pipeline updates RSS